Crinetics Pharmaceuticals CRNX Accrued compensation and related expenses
Accrued compensation and related expenses at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:AccruedCompensationAndRelatedExpense.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's accrued compensation and related expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's accrued compensation and related expenses?
- Crinetics Pharmaceuticals (CRNX) reported accrued compensation and related expenses of $25.79M in Q1 2026.
- How has Crinetics Pharmaceuticals's accrued compensation and related expenses changed year-over-year?
- Crinetics Pharmaceuticals's accrued compensation and related expenses increased by 55.3% year-over-year, from $16.61M to $25.79M.
- What is the long-term trend for Crinetics Pharmaceuticals's accrued compensation and related expenses?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's accrued compensation and related expenses has grown at a 54.3% compound annual growth rate (CAGR), from $4.07M to $35.58M.
- What does accrued compensation and related expenses mean?
- This liability captures the total obligation for employee-related costs, including salaries, bonuses, and benefits, that have been earned by staff but not yet paid at the balance sheet date. It serves as a measure of short-term operational obligations related to human capital. Monitoring this helps investors understand the company's immediate cash requirements for maintaining its workforce.